CD4-Targeted CAR-Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia 2224687
In vivo, CAR4-DNT achieved durable leukemia clearance and prolonged survival, whereas PBS-treated mice rapidly progressed and UT-DNT recipients showed transient disease control before relapse, establishing CAR4-DNTs as a promising immunotherapy candidate for AML, supporting their further preclinical and translational development.